The WHO Solidarity Trial has brought together more than 100 countries to find effective therapies for COVID-19 as quickly as possible. IFPMA members have also been searching their drug libraries for potentially safe and effective options that could help develop new or repurposed treatments. The FDA, in the US, approved Gilead’s remdesivir as the first COVID-19 treatment. In May and by the EMA in June. On July 24, the EMA began reviewing the results of the RECOVERY clinical trial of dexamethasone to treat cases of adults requiring respiratory support.
The following IFPMA member companies have partnered with the COVID-19 Therapeutic Accelerator initiative, initiated by the Gates Foundation, Welcome, and MasterCard, to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the US and Canada), Merck KGaA, Novartis, Pfizer, and Sanofi.
NIH established the public-private partnership Accelerating COVID-19 Vaccines and Therapeutic Interventions (ACTIV) to develop a coordinated research strategy to prioritize and accelerate the development of the most promising treatments and vaccines. The following IFPMA member companies have collaborated with the ACTIV initiative: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Gilead, GSK, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, Roche -Genentech, Sanofi, and Takeda.
As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the biopharmaceutical industry is in a unique position to respond rapidly to Covid-19. Our sector has gained in-depth scientific knowledge from decades of experience developing solutions for infectious diseases such as MERS, SARS, Ebola, and influenza and working with health and regulatory authorities to develop and deliver safe medicines, vaccines, and diagnostics and useful to patients.
The rapid worldwide spread of SARS-CoV-2 is a public health emergency. Today more than ever, we need practical international cooperation to ensure that no one is left behind in the race to deal with this crisis. This requires the coordinated action of multiple stakeholders, including the private sector as a critical partner. The IFPMA members, of which AMIIF is a part, are fully committed to contributing their unique expertise in the research, development, and manufacturing of therapeutic, vaccine, and diagnostic products.
Pfizer confirmed a parent compound and its analogs as potent inhibitors of SARS CoV-2 type 3C protease. Furthermore, preliminary data suggest that the significant protease inhibitor exhibits antiviral activity against SARS CoV-2. Now, Pfizer will conduct preclinical confirmation studies.
Pfizer shared in vitro and clinical data on azithromycin, which could be used in future COVID-19 research.